摘要: Despite intensive clinical research efforts of the past 15 years, little real progress has been made in management lung cancer, and outlook for patients whose tumors cannot be completely resected remains grim. Obviously, surgical radiotherapeutic treatment modalities are approaching limits their potential efficacies, early promise combination chemotherapy only partially realized. New cytotoxic agents with significant activity cancer difficult to find, results trials biological such as interferons or interleukins raise hope major activity.